

OCT 12 2007

Appn. Number 10/811,413 (Sung et al.) GAU 1615 Amnt. A contd. Page 4

AMENDMENTS TO THE CLAIMS:

Please cancel claims 1-2, 4, 6-17, and 19-20. Please amend claims 3, 5, and 18. Please add new claims 21-30.

A complete listing of all claims and their current status is presented below.

1-2.(cancelled)

3.(currently amended) ~~The stent according to claim 1,~~ A biodegradable stent for treating vulnerable plaques or atherosclerotic plaques of a patient comprising:

at least two zones, wherein a first supporting zone comprises a first biodegradable material; and

a second therapeutic zone comprising a second biodegradable material, wherein at least one of the first and the second biodegradable material is a shape memory polymer.

4.(cancelled)

5.(currently amended) ~~The stent according to claim 4,~~ A biodegradable stent for treating vulnerable plaques or atherosclerotic plaques of a patient comprising:

at least two zones, wherein a first supporting zone comprises a first biodegradable material;

a second therapeutic zone comprising a second biodegradable material, wherein at least one of the first and the second biodegradable material further comprises a biological material, wherein said biological material is crosslinked with a crosslinking agent or with ultraviolet irradiation; and

~~wherein said biological material is crosslinked with a crosslinking agent,~~ wherein the crosslinking agent is genipin, its analog, derivatives, and combination thereof.

6-17.(cancelled)

18.(currently amended) ~~The stent according to claim 11,~~ A biodegradable stent for treating vulnerable plaques or atherosclerotic plaques of a patient comprising:

at least two zones, wherein a first supporting zone comprises a first biodegradable material;

a second therapeutic zone comprising a second biodegradable material, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises lipostabil.

19-20.(cancelled)

21.(new) The stent according to claim 5, wherein said biological material is selected from the group consisting of collagen, gelatin, elastin, chitosan, N, O, carboxymethyl chitosan, and mixture thereof.

22.(new) Te stent according to claim 5, wherein at least one of the first and the second biodegradable material is a shape memory polymer.

23.(new) Te stent according to claim 5, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent.

24.(new) Te stent according to claim 5, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises lipostabil.

25.(new) Te stent according to claim 5, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises analgesics/antipyretics.

26.(new) Te stent according to claim 5, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises ApoA-I Milano or recombinant ApoA-I Milano/phospholipid complexes.

27.(new) Te stent according to claim 5, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises a growth factor.

28.(new) Te stent according to claim 5, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises everolimus.

29.(new) Te stent according to claim 5, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises angiotensin converting enzyme inhibitors.

30.(new) The stent according to claim 5, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises endothelial progenitor cells.